21 CFR Part 11 and EU Annex 11 both govern electronic records in pharma — but they differ in scope, approach, and specific technical requirements. For global operations, satisfying one does not automatically satisfy the other. This side-by-side breakdown covers exactly where they diverge and what your paperless validation system must address to meet both.
The Two Frameworks at a Glance
Key Differences: Side-by-Side
| Area | 21 CFR Part 11 (FDA) | EU Annex 11 (EMA) |
|---|---|---|
| Nature | Regulation Legally binding, prescriptive technical requirements | Guideline Principles-based, risk assessment determines controls |
| Scope | Electronic records that replace paper records required by predicate rules | All computerised systems used in GxP environments — broader than records alone |
| Audit Trail | Required for records created, modified, or deleted. Must capture date, time, and who made the change | Same core requirement — additionally requires audit trails to be regularly reviewed as part of routine operations |
| Electronic Signatures | Prescriptive: must be uniquely linked to individual, include date/time, include meaning of signature | Principles-based: must be uniquely attributable and equivalent to handwritten — specific implementation left to risk assessment |
| Supplier / Vendor | Not explicitly addressed — implied through system validation | Explicit clause (3): supplier must be assessed for suitability; formal agreement required covering responsibilities and quality standards |
| Data Backup & Recovery | Not prescribed — implied through predicate rule requirements | Explicit requirement for data backup, disaster recovery, and business continuity procedures |
| Risk Assessment | Not explicitly required — Part 11 controls apply uniformly | Explicitly required — risk assessment determines the appropriate level of validation and controls for each system |
| Periodic Review | Not specifically required | Explicitly required — systems must be periodically evaluated to confirm they remain in a validated state |
Where They Fully Align
How GoVal Satisfies Both Frameworks
GoVal is built for global pharma operations that cannot afford to run separate validation systems for US and EU compliance. Every module is designed to satisfy both frameworks simultaneously:
- ✓Audit trails — tamper-evident, time-stamped, capturing every record creation, modification, approval, and deletion. Meets both Part 11's prescription and Annex 11's regular review expectation.
- ✓E-signatures — uniquely attributed with meaning, date, and time. Satisfies Part 11 §11.50 and Annex 11's attribution requirements simultaneously.
- ✓Vendor Assessment Package — provided at onboarding to satisfy Annex 11 clause 3 supplier qualification requirements. Covers system architecture, security, and quality agreements.
- ✓Validated data backup and DR — documented backup procedures and recovery testing satisfy Annex 11's explicit business continuity requirement.
- ✓Periodic review workflows — built-in review scheduling ensures systems remain in a validated state — satisfying Annex 11's periodic evaluation requirement without manual calendar management.
Frequently Asked Questions
What is the main difference between EU Annex 11 and 21 CFR Part 11? +
Do both frameworks apply to validation management software? +
What is the best validation software for EU compliance? +
What is the best validation software for FDA compliance? +
What does EU Annex 11 require for supplier management? +
How does GoVal help satisfy both EU Annex 11 and 21 CFR Part 11? +
One platform. Both frameworks. Zero duplicate overhead.
GoVal is purpose-built to satisfy 21 CFR Part 11 and EU Annex 11 simultaneously — in a pre-validated VLMS your team can deploy in 3–6 weeks.
Book a Free Demo →
